DK1836312T3 - Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration - Google Patents

Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration

Info

Publication number
DK1836312T3
DK1836312T3 DK05851755.8T DK05851755T DK1836312T3 DK 1836312 T3 DK1836312 T3 DK 1836312T3 DK 05851755 T DK05851755 T DK 05851755T DK 1836312 T3 DK1836312 T3 DK 1836312T3
Authority
DK
Denmark
Prior art keywords
macular degeneration
related macular
diagnoses
age
compositions
Prior art date
Application number
DK05851755.8T
Other languages
English (en)
Inventor
Josephine Hoh
Robert J Klein
Original Assignee
Univ Yale
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ Rockefeller filed Critical Univ Yale
Application granted granted Critical
Publication of DK1836312T3 publication Critical patent/DK1836312T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK05851755.8T 2004-11-18 2005-11-18 Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration DK1836312T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US64947905P 2005-02-02 2005-02-02
US67234605P 2005-04-18 2005-04-18
PCT/US2005/041664 WO2006062716A2 (en) 2004-11-18 2005-11-18 Methods and compositions for treating ocular disorders

Publications (1)

Publication Number Publication Date
DK1836312T3 true DK1836312T3 (da) 2012-03-12

Family

ID=36578383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05851755.8T DK1836312T3 (da) 2004-11-18 2005-11-18 Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration

Country Status (15)

Country Link
US (3) US20090017029A1 (da)
EP (1) EP1836312B1 (da)
JP (2) JP2008520242A (da)
KR (1) KR101290621B1 (da)
CN (2) CN102618644A (da)
AT (1) ATE528410T1 (da)
AU (1) AU2005314461B2 (da)
BR (1) BRPI0518289A2 (da)
CA (1) CA2588270A1 (da)
CY (1) CY1112579T1 (da)
DK (1) DK1836312T3 (da)
ES (1) ES2375490T3 (da)
HK (1) HK1113690A1 (da)
IL (1) IL183284A (da)
WO (1) WO2006062716A2 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505784A1 (en) 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
AU2007215218B2 (en) * 2006-02-13 2013-09-19 National Institutes Of Health Variants in complement regulatory genes predict age-related macular degeneration
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
ATE551350T1 (de) * 2006-07-13 2012-04-15 Univ Iowa Res Found Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
WO2009059317A2 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
SI2540843T1 (sl) 2008-11-05 2014-10-30 Genentech, Inc. Genetski polimorfizmi in starostna degeneracija makule
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
EP2533797A1 (en) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Complement factor h for oxidative stress disease conditions
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
WO2011153234A2 (en) * 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
SI2968457T1 (sl) 2013-03-14 2018-11-30 Baxalta Incorporated Faktor H za transplantacijo
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
US9248162B2 (en) 2013-03-14 2016-02-02 Baxalta Incorporated Factor H for treatment of rheumatoid arthritis
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN106248969A (zh) * 2015-11-01 2016-12-21 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
CN108474039B (zh) * 2015-12-03 2022-06-07 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020019002A1 (en) * 2018-07-20 2020-01-23 University Of Utah Research Foundation Gene therapy for macular degeneration
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
JP2002520287A (ja) * 1998-07-10 2002-07-09 ザ・ユニバーシティ・オブ・シドニー 黄斑変性における血管新生の予防的治療
US20020032319A1 (en) * 2000-03-07 2002-03-14 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
DE60136272D1 (de) * 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂

Also Published As

Publication number Publication date
JP2012080900A (ja) 2012-04-26
KR101290621B1 (ko) 2013-07-29
EP1836312A2 (en) 2007-09-26
CN101142321A (zh) 2008-03-12
IL183284A0 (en) 2007-09-20
WO2006062716A2 (en) 2006-06-15
HK1113690A1 (en) 2008-10-10
CY1112579T1 (el) 2016-02-10
AU2005314461A1 (en) 2006-06-15
US20140018306A1 (en) 2014-01-16
WO2006062716A3 (en) 2006-10-05
ES2375490T3 (es) 2012-03-01
AU2005314461B2 (en) 2012-02-02
CN101142321B (zh) 2012-06-06
ATE528410T1 (de) 2011-10-15
EP1836312B1 (en) 2011-10-12
JP2008520242A (ja) 2008-06-19
CA2588270A1 (en) 2006-06-15
KR20070105969A (ko) 2007-10-31
US20090017029A1 (en) 2009-01-15
US20120135000A1 (en) 2012-05-31
CN102618644A (zh) 2012-08-01
BRPI0518289A2 (pt) 2008-11-11
IL183284A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
DK1836312T3 (da) Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20070510L (no) Fremgangsmater og reagenser for behandling av metabole forstyrrelser
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006079101A3 (en) Associations using genotypes and phenotypes
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
ATE551350T1 (de) Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
NO20054953D0 (no) Fremgangsmate og program for rekonstruksjon av frakturplan
DE602007011566D1 (en) Ankheit
EA201291206A1 (ru) Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
NO20085224L (no) Vurdering av funksjonell status
DE602005012530D1 (de) Immunogene glykopeptide zur diagnose von infektionen pathogener mikroorganismen
DE602004029061D1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
MA29700B1 (fr) Vaccin
ATE490339T1 (de) Diagnostikum für osteoporose
NO20070780L (no) Celloverflateprotein.
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
DK1907579T3 (da) Fremgangsmåde til diagnose af glioma ved at skelne mellem typerne progressive og denovo
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2006032021A3 (en) Identification of gene associated with reading disability and uses therefor